Cytomedix, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
39 Pages - GMD12093


Global Markets Direct’s, ‘Cytomedix, Inc. - Product Pipeline Review - 2014’, provides an overview of the Cytomedix, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cytomedix, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Cytomedix, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cytomedix, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Cytomedix, Inc.’s pipeline products

Reasons to buy

- Evaluate Cytomedix, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cytomedix, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cytomedix, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cytomedix, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cytomedix, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cytomedix, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cytomedix, Inc. Snapshot 5
Cytomedix, Inc. Overview 5
Key Information 5
Key Facts 5
Cytomedix, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Cytomedix, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Cytomedix, Inc. - Pipeline Products Glance 10
Cytomedix, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Cytomedix, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Cytomedix, Inc. - Drug Profiles 13
ALD-301 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
ALD-401 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ALD-151 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
ALD-201 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ALD-451 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ALD-601 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CT-112 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Cytomedix, Inc. - Pipeline Analysis 21
Cytomedix, Inc. - Pipeline Products by Route of Administration 21
Cytomedix, Inc. - Pipeline Products by Molecule Type 22
Cytomedix, Inc. - Recent Pipeline Updates 23
Cytomedix, Inc. - Discontinued Pipeline Products 27
Discontinued Pipeline Product Profiles 27
ALD-101 27
Cytomedix, Inc. - Company Statement 28
Cytomedix, Inc. - Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables
Cytomedix, Inc., Key Information 5
Cytomedix, Inc., Key Facts 5
Cytomedix, Inc. - Pipeline by Indication, 2014 7
Cytomedix, Inc. - Pipeline by Stage of Development, 2014 8
Cytomedix, Inc. - Monotherapy Products in Pipeline, 2014 9
Cytomedix, Inc. - Phase II, 2014 10
Cytomedix, Inc. - Phase I, 2014 11
Cytomedix, Inc. - Preclinical, 2014 12
Cytomedix, Inc. - Pipeline by Route of Administration, 2014 21
Cytomedix, Inc. - Pipeline by Molecule Type, 2014 22
Cytomedix, Inc. - Recent Pipeline Updates, 2014 23
Cytomedix, Inc. - Discontinued Pipeline Products, 2014 27
Cytomedix, Inc., Subsidiaries 37

List of Figures
Cytomedix, Inc. - Pipeline by Top 10 Indication, 2014 7
Cytomedix, Inc. - Pipeline by Stage of Development, 2014 8
Cytomedix, Inc. - Monotherapy Products in Pipeline, 2014 9
Cytomedix, Inc. - Pipeline by Top 10 Route of Administration, 2014 21
Cytomedix, Inc. - Pipeline by Top 10 Molecule Type, 2014 22


Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.
+1 212 564 2838
+1 212 564 8133 fax